QuidelOrtho (QDEL) Stock Overview
Provides diagnostic testing solutions. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
QDEL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
QuidelOrtho Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.00 |
| 52 Week High | US$35.58 |
| 52 Week Low | US$9.92 |
| Beta | 0.69 |
| 1 Month Change | 18.63% |
| 3 Month Change | 10.97% |
| 1 Year Change | -44.84% |
| 3 Year Change | -80.32% |
| 5 Year Change | -85.57% |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Narrative Update • Jun 30
QDEL: Unit Sale Plans And Reimbursement Shift Will Shape Future Upside
The analyst price target for QuidelOrtho has been reduced from about $34.67 to $18.63, as analysts reset fair value assumptions and forward P/E expectations, while incorporating updated views on revenue growth and profit margins reflected in recent research reports. Analyst Commentary Recent research on QuidelOrtho highlights a mix of optimism about the company’s long term potential and concern about near term execution, which together have driven multiple cuts to price targets and, in at least one case, a downgrade in rating.
Narrative Update • Jun 16
QDEL: Reset Expectations And China Reimbursement Changes Will Support Future Earnings
QuidelOrtho's analyst price target has been reduced by a combined $17 in recent updates, as analysts reassess expectations around revenue growth, profit margins, and forward P/E assumptions, as reflected in the latest research from several major firms. Analyst Commentary Recent research on QuidelOrtho reflects a more cautious tone on price targets, but there are still several constructive points that bullish analysts highlight when they look at the stock's setup and valuation framework.Narrative Update • Jun 02
QDEL: Evolving China Reimbursement Rules Will Support Future Earnings Potential
Narrative Update Analysts have trimmed their QuidelOrtho price targets by single digits in recent research, citing updated views on revenue growth, profit margins, and an updated forward P/E framework, which together support a reset in fair value to $38.00. Analyst Commentary Recent Street research has centered on valuation resets for QuidelOrtho, with several firms revisiting assumptions around revenue growth, margin structure, and the appropriate P/E range.Seeking Alpha • May 12
QuidelOrtho: A Growing, Stable Business With A Significant Mispricing
Summary QuidelOrtho's core lab testing and immunohematology businesses account for over 75% of sales, where customers sign 5-7-year contracts and the company boasts a contract renewal rate exceeding 95%. While QuidelOrtho missed its 2025 free cash flow guidance due to accounts receivable issues, the company successfully recovered roughly half of that increase during the first quarter. Management models the Chinese reimbursement policy change as a $70 million EBITDA hit, with the impact felt almost entirely in the next 18 months. QuidelOrtho believes LEX has a strong chance of turning the company's respiratory business back into a growth engine after losing share to rival molecular diagnostics competitors. QuidelOrtho retains substantial flexibility to address debt, such as selling the immunohematology division or exiting its capital-intensive leasing business to reduce leverage. Read the full article on Seeking Alpha
Narrative Update • May 08
QDEL: Earnings Headwinds And China Reimbursement Risks Will Likely Limit Share Upside
Analysts have reduced the QudelOrtho fair value estimate from $22.00 to $11.00, reflecting updated views on slower revenue growth, slightly lower profit margins, a higher discount rate, and a lower future P/E multiple following recent price target cuts and a downgrade in Street research. Analyst Commentary Recent Street research on QuidelOrtho reflects a more cautious tone, with several price target cuts and at least one downgrade contributing to the lower fair value estimate.Narrative Update • Apr 23
QDEL: Expanded Immunoassay Partnership Will Support Future Earnings Potential Under Evolving Reimbursement Rules
Analysts have trimmed their 12 month price target on QuidelOrtho by $12 to about $38, reflecting updated assumptions around slightly lower revenue growth, an unchanged discount rate, and a lower future P/E multiple in light of recent Street research on reimbursement and competitive dynamics. Analyst Commentary Recent Street research presents a mixed picture for QuidelOrtho, with some analysts trimming price targets while others maintain a constructive view on the company’s longer term positioning and valuation framework.Narrative Update • Apr 09
QDEL: Expanded Immunoassay Partnership Will Shape Future Earnings Potential Under Evolving Reimbursement Rules
QuidelOrtho's analyst price target has been adjusted to $50.00. Analysts cite updated assumptions around revenue growth, profit margins, and future P/E expectations in light of recent reimbursement and sector research.Narrative Update • Mar 26
QDEL: Lifotronic Supply Agreement And Reimbursement Shift Will Shape Future Upside
QuidelOrtho's consensus analyst price target has been adjusted to $34.67. Analysts point to a slightly higher discount rate, modestly lower profit margin assumptions and a higher future P/E multiple as they factor in recent reimbursement policy commentary and mixed target moves from UBS, JPMorgan and Citi.Narrative Update • Mar 10
QDEL: Expanded Immunoassay Partnership Will Reshape Future Earnings Power
QuidelOrtho's updated analyst price target moves to $50, reflecting revised assumptions on fair value, discount rate, revenue growth, profit margin, and future P/E that align with recent mixed target changes from analysts across the Street. Analyst Commentary Recent Street research on QuidelOrtho has been mixed, with both upward and downward price target revisions.Narrative Update • Feb 24
QDEL: Long Term Lifotronic Supply Agreement Will Support Future Upside
QuidelOrtho's blended analyst price target has shifted from roughly $38.33 to $34.67 as analysts refresh their models around updated growth, profitability and P/E assumptions following mixed target revisions from several major firms. Analyst Commentary Recent research updates on QuidelOrtho point to a mixed but active debate around the stock, with several firms adjusting their price targets in both directions as they revisit growth and profitability assumptions.Narrative Update • Feb 09
QDEL: Refined Earnings Assumptions Will Likely Constrain Future Share Performance
Analysts have lifted their price target on QuidelOrtho by $4 to $22, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E that refine their view of the company’s risk and earnings profile. Analyst Commentary Recent research points to a more measured stance on QuidelOrtho, even with the updated US$22 price target.Narrative Update • Jan 24
QDEL: New Cardiac Assay Clearance And Guidance Will Support Future Upside
Analysts lifted their price target on QuidelOrtho by about $1 to roughly $38. The revised target reflects updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions.Analysis Article • Jan 11
QuidelOrtho (NASDAQ:QDEL) Use Of Debt Could Be Considered Risky
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Narrative Update • Jan 10
QDEL: Future Earnings Multiple And Modest Growth Assumptions Will Pressure Shares
Analysts have kept their price target for QuidelOrtho steady at US$22.00, citing updated assumptions around a slightly lower discount rate, a modestly higher revenue growth outlook at 3.40%, a broadly similar profit margin near 12.90% and a future P/E of about 5.30x. What's in the News QuidelOrtho issued fiscal 2025 guidance, with total revenues projected in a range of US$2.68b to US$2.74b, offering investors a reference point for its near term business expectations (company guidance).Narrative Update • Dec 21
QDEL: Elevated Return Demands Will Pressure Shares Despite New Diagnostic Launches
Analysts have reduced their price target on QuidelOrtho by 4 dollars, from 26 dollars to 22 dollars, citing a slightly higher required return despite modestly stronger expectations for revenue growth and profit margins. What's in the News QuidelOrtho issued fiscal 2025 guidance, projecting total revenues between 2.68 billion and 2.74 billion dollars, signaling confidence in sustained growth (Key Developments).Narrative Update • Dec 07
QDEL: New Cardiac And Respiratory Test Approvals Will Drive Shares Higher
Analysts have modestly revised their price target for QuidelOrtho upward to approximately 37.67 dollars per share, citing a slightly lower perceived risk profile reflected in the reduced discount rate, while keeping revenue growth and valuation expectations largely unchanged. What's in the News Issued fiscal 2025 revenue guidance of 2.68 billion to 2.74 billion dollars, signaling steady growth expectations despite a challenging diagnostics backdrop (company guidance) Received FDA 510(k) clearance for the VITROS hs Troponin I Assay for quantitative cardiac troponin I measurement to aid in myocardial infarction diagnosis, with U.S. commercial rollout planned later this year (FDA clearance announcement) Expanded its QUICKVUE portfolio with the CLIA waived, 510(k) cleared QUICKVUE Influenza + SARS rapid combo test, enabling simultaneous detection of influenza A, influenza B and SARS CoV 2 from a single sample in about 10 minutes (product launch announcement) Valuation Changes The fair value estimate is unchanged at approximately 37.67 dollars per share, indicating a stable central valuation view.Narrative Update • Nov 23
QDEL: Expanding Test Portfolio And Profit Margin Will Drive Share Price Higher
Narrative Update on QuidelOrtho: Analyst Price Target Revision Analysts have notably raised QuidelOrtho's price target to $37.67, citing improvements in the company's profit margin and future price-to-earnings expectations as key drivers for the upward revision. What's in the News QuidelOrtho issued fiscal 2025 financial guidance and forecasted total revenues between $2.68 billion and $2.74 billion (Company announcement).Analysis Article • Nov 20
Lacklustre Performance Is Driving QuidelOrtho Corporation's (NASDAQ:QDEL) 28% Price Drop
QuidelOrtho Corporation ( NASDAQ:QDEL ) shareholders won't be pleased to see that the share price has had a very rough...Analysis Article • Nov 09
QuidelOrtho Corporation (NASDAQ:QDEL) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
There's been a major selloff in QuidelOrtho Corporation ( NASDAQ:QDEL ) shares in the week since it released its...Narrative Update • Nov 09
QDEL: Product Approvals And Rural Expansion Will Drive Further Outperformance
QuidelOrtho's analyst price target has been lowered from $40.33 to $37.67. This reflects adjustments to discount rates and margin forecasts as analysts re-evaluate the company's outlook.Narrative Update • Sep 28
Global Expansion And Decentralized Testing Will Unlock Future Potential
Analysts have modestly reduced their price targets for QuidelOrtho to $40.33, reflecting a cautious outlook despite solid quarterly results and prudent guidance, as the market awaits further proof of sustainable performance. Analyst Commentary Revenues for the quarter were roughly in line with estimates, with Labs outperforming expectations and respiratory revenues meeting expectations.Narrative Update • Aug 07
Global Expansion And Decentralized Testing Will Unlock Future Potential
The consensus analyst price target for QuidelOrtho has been revised downward, primarily reflecting a sharp deterioration in profitability—evidenced by a collapse in net profit margin and a spike in the future P/E ratio—with fair value lowered from $47.14 to $43.57. What's in the News QuidelOrtho reiterated its full year 2025 earnings guidance, with expected revenues between $2.60 billion and $2.81 billion.Analysis Article • May 14
QuidelOrtho Corporation (NASDAQ:QDEL) Surges 32% Yet Its Low P/S Is No Reason For Excitement
Those holding QuidelOrtho Corporation ( NASDAQ:QDEL ) shares would be relieved that the share price has rebounded 32...Analysis Article • Apr 25
QuidelOrtho (NASDAQ:QDEL) Has No Shortage Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysis Article • Mar 30
QuidelOrtho Corporation's (NASDAQ:QDEL) Business And Shares Still Trailing The Industry
With a price-to-sales (or "P/S") ratio of 0.8x QuidelOrtho Corporation ( NASDAQ:QDEL ) may be sending very bullish...
New Narrative • Mar 21
Leadership Changes And Cost Reductions Will Shape Future Profitability
Leadership changes and strategic initiatives aim for innovation and efficiency, enhancing revenue and net margins.Seeking Alpha • Feb 20
QuidelOrtho: Growth Struggles And Negative GAAP Earnings Continue To Disinterest Investors
Summary QuidelOrtho Corporation's 2023 operating cash flow estimate missed significantly, raising doubts about management's projections and affecting investor confidence. Despite growth in the Labs business, QDEL reported its fourth consecutive quarter of negative GAAP earnings, increasing investment risk. Long-term technicals show QDEL shares are oversold, but breaking long-term support questions the potential for a near-term bull run. We maintain a 'Hold' rating due to stagnant growth, poor forward-looking revenue revisions, and concerning technicals, suggesting QDEL may need further restructuring. Read the full article on Seeking AlphaShareholder Returns
| QDEL | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -2.9% | 3.1% | 0.8% |
| 1Y | -44.8% | -18.2% | 20.2% |
Return vs Industry: QDEL underperformed the US Medical Equipment industry which returned -18.2% over the past year.
Return vs Market: QDEL underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| QDEL volatility | |
|---|---|
| QDEL Average Weekly Movement | 17.0% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: QDEL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: QDEL's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 6,500 | Brian Blaser | www.quidelortho.com |
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.
QuidelOrtho Corporation Fundamentals Summary
| QDEL fundamental statistics | |
|---|---|
| Market cap | US$1.23b |
| Earnings (TTM) | -US$1.21b |
| Revenue (TTM) | US$2.66b |
0.4x
P/S Ratio-1.0x
P/E RatioIs QDEL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QDEL income statement (TTM) | |
|---|---|
| Revenue | US$2.66b |
| Cost of Revenue | US$1.46b |
| Gross Profit | US$1.20b |
| Other Expenses | US$2.41b |
| Earnings | -US$1.21b |
Last Reported Earnings
Mar 29, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -17.76 |
| Gross Margin | 45.18% |
| Net Profit Margin | -45.57% |
| Debt/Equity Ratio | 145.2% |
How did QDEL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/07 21:35 |
| End of Day Share Price | 2026/07/07 00:00 |
| Earnings | 2026/03/29 |
| Annual Earnings | 2025/12/28 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
QuidelOrtho Corporation is covered by 20 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | Canaccord Genuity |
| Patrick Donnelly | Citigroup Inc |
| Jose De Jesus Haresco | Citizens JMP Securities, LLC |